Still Taking Wegovy® or Zepbound®?

You may qualify for a research study evaluating a less-frequent dosing option.

If you’ve already lost weight with Wegovy® or Zepbound® and have been on the same dose for at least 6 months, you may qualify for a local clinical research study.

Compensation may be available for time and travel.

This Study May Be Right For You If:

✓ You are 18 years of age or older
✓ You have overweight or obesity
✓ You have been taking brand-name Wegovy® or Zepbound®
✓ Your medication dose has stayed the same for about 6 months
✓ You’ve already lost 10% or more of your body weight
✓ Your weight has remained relatively stable over the past 6 months
✓ You do not have diabetes

These are only some of the study requirements. A member of our research team will review all eligibility criteria with you.

What Is This Study?

Researchers are evaluating an investigational medication that may allow people who are successfully managing their weight on weekly GLP-1 medications to switch to a treatment that is taken less often.

The goal is to learn whether people can continue maintaining their weight loss with a less-frequent dosing schedule.

Why Participate?

Participants may receive:

Study-related medical care at no cost
Study medication provided as part of the research
Compensation for time and travel
Care from an experienced clinical research team
The opportunity to help advance future obesity treatments

Before You Apply

To save you time, this study is primarily looking for people who are currently taking:

Wegovy®

1.7 mg
2.4 mg

Zepbound®

5 mg
7.5 mg
10 mg
12.5 mg
15 mg

…and have been on the same dose for approximately 6 months.

People taking compounded or generic versions of semaglutide or tirzepatide are not eligible for this study.

Complete the interest form to learn more and see how you may qualify.

Atlas Clinical Research